INT574

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1975
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 13
Disease Relevance 11.25
Pain Relevance 1.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (C1S) extracellular region (C1S)
Anatomy Link Frequency
plasma 4
mitral valve 1
C1S (Homo sapiens)
Pain Link Frequency Relevance Heat
corticosteroid 3 97.28 Very High Very High Very High
Antihistamine 2 95.68 Very High Very High Very High
bradykinin 25 94.28 High High
lidocaine 4 91.84 High High
Pain 23 83.56 Quite High
spastic colon 1 83.44 Quite High
abdominal pain 14 83.28 Quite High
rheumatoid arthritis 1 75.76 Quite High
cva 12 71.76 Quite High
headache 4 65.76 Quite High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 174 99.98 Very High Very High Very High
Hereditary Angioedema 227 99.84 Very High Very High Very High
Emergencies 7 98.06 Very High Very High Very High
Injury 20 97.56 Very High Very High Very High
Airway Obstruction 2 97.52 Very High Very High Very High
Pressure And Volume Under Development 131 97.08 Very High Very High Very High
Congenital Anomalies 3 97.08 Very High Very High Very High
Membranous Glomerulonephritis 34 95.52 Very High Very High Very High
Vomiting 5 93.36 High High
Abdominal Cramps 1 91.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It is the main inhibitor of C1r and C1s of the complement system.
Negative_regulation (inhibitor) of C1s
1) Confidence 0.47 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2887436 Disease Relevance 0.64 Pain Relevance 0.04
The full benefit of reducing LDL-C is only now being tested in adequate clinical trials.



Negative_regulation (reducing) of C is
2) Confidence 0.42 Published 2001 Journal Curr Control Trials Cardiovasc Med Section Abstract Doc Link PMC59651 Disease Relevance 0.48 Pain Relevance 0
When C1 esterase inhibitor is depleted in these patients, vasoactive plasma cascade products cause swelling attacks.
Negative_regulation (inhibitor) of C1 esterase in plasma associated with pressure and volume under development
3) Confidence 0.42 Published 2010 Journal J Cardiothorac Surg Section Abstract Doc Link PMC2965712 Disease Relevance 1.17 Pain Relevance 0.08
Patients with hereditary angioedema cannot replenish C1 esterase inhibitor levels on pace with its binding.
Negative_regulation (replenish) of C1 esterase associated with hereditary angioedema
4) Confidence 0.42 Published 2010 Journal J Cardiothorac Surg Section Abstract Doc Link PMC2965712 Disease Relevance 1.17 Pain Relevance 0.08
One potential mechanism of increasing HDL-C is inhibition of cholesteryl ester transfer protein (CETP).
Negative_regulation (inhibition) of C is associated with disorder of lipid metabolism
5) Confidence 0.41 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.66 Pain Relevance 0.31
Subsequently, total hemolytic activity (CH50) levels were variable, complement component protein concentrations of C1q, C1s, C4, C2, C3, C5, C6, C9, and Factor B were normal, but hemolytic activity of C4 and C2 was diminished.
Negative_regulation (diminished) of C1s
6) Confidence 0.41 Published 1975 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 50336 Disease Relevance 0.31 Pain Relevance 0.38
The plasma concentrations of C1-esterase inhibitor (5.6 mg/dl) and of complement factor C4 (10.0 mg/dl) were reduced.
Negative_regulation (inhibitor) of C1-esterase in plasma
7) Confidence 0.34 Published 1997 Journal Dtsch. Med. Wochenschr. Section Body Doc Link 9410707 Disease Relevance 0.27 Pain Relevance 0
Three medications are available for acute treatment of HAE: Berinert-P® (plasma-derived C1 esterase inhibitor, approved in the US and Europe), KALBITOR® (ecallantide, a kallikrein inhibitor, approved only in the US currently), and Firazyr® (icatibant, bradykinin ?
Negative_regulation (inhibitor) of C1 esterase in plasma associated with hereditary angioedema and bradykinin
8) Confidence 0.31 Published 2010 Journal J Cardiothorac Surg Section Body Doc Link PMC2965712 Disease Relevance 0.56 Pain Relevance 0.05
However, newer agents are approved for long-term prophylaxis (C1 esterase inhibitor [CINRYZE™]) and acute attacks (C1 esterase inhibitor [Berinert P®] and kallikrein inhibitor, ecallantide [KALBITOR®]).
Negative_regulation (inhibitor) of C1 esterase
9) Confidence 0.31 Published 2010 Journal J Cardiothorac Surg Section Body Doc Link PMC2965712 Disease Relevance 1.00 Pain Relevance 0.04
We report a case of successful short-term prophylaxis with C1 esterase inhibitor in a 51-year-old man with hereditary angioedema who underwent redo mitral valve reconstructive surgery.



Negative_regulation (inhibitor) of C1 esterase in mitral valve associated with hereditary angioedema
10) Confidence 0.31 Published 2010 Journal J Cardiothorac Surg Section Abstract Doc Link PMC2965712 Disease Relevance 1.07 Pain Relevance 0.06
The serum concentrations of C3, C4, and C1 esterase inhibitor remained unchanged.
Negative_regulation (inhibitor) of C1 esterase
11) Confidence 0.22 Published 1991 Journal Scand. J. Gastroenterol. Section Abstract Doc Link 1827928 Disease Relevance 0.65 Pain Relevance 0.08
The emergency treatment of HAE includes purified C1 INH concentrate infusion or fresh frozen plasma (contains C1 esterase inhibitor) and/or subcutaneous adrenaline.
Negative_regulation (inhibitor) of C1 esterase in plasma associated with emergencies
12) Confidence 0.19 Published 2008 Journal J Med Case Reports Section Body Doc Link PMC2577685 Disease Relevance 0.86 Pain Relevance 0.10
Investigations were consistent with type 1 HAE, showing low C1 esterase inhibitor activity of 0.06 g/litre (normal range [NR] 0.2 to 0.65 g/litre), low complement C4 and normal complement C3.
Negative_regulation (inhibitor) of C1 esterase
13) Confidence 0.19 Published 2008 Journal J Med Case Reports Section Body Doc Link PMC2577685 Disease Relevance 1.41 Pain Relevance 0.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox